Physician profile
Jacklyn Lerner
NPI 1518720994
$9,563.20
in general payments reported to CMS, 2019-2025
29 companies · $5,495 in 2025
The $5,495 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,068 · 2025: $5,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,536 · Education: $27.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,536.01 |
| Education | $27.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,657.06 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,118.63 | 2024-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $944.69 | 2024-2025 | Caplyta |
| Lundbeck LLC | $477.17 | 2024-2025 | Rexulti |
| Corium, LLC | $476.11 | 2024-2025 | Azstarys |
| Tris Pharma INC | $426.64 | 2024-2025 | Dyanavel Xr |
| Neuronetics, INC. | $421.09 | 2024-2025 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $409.46 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $403.07 | 2024-2025 | Qelbree |
| Almatica Pharma LLC | $365.01 | 2024-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $331.00 | 2024-2025 | Xelstrym, Secuado |
| Janssen Pharmaceuticals, INC | $324.00 | 2024-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $316.50 | 2024-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $273.01 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $263.18 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $261.77 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Bausch Health US, LLC | $234.18 | 2024-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $159.88 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $124.32 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $114.18 | 2024-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $104.40 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $95.05 | 2024 | |
| Sage Therapeutics, LLC | $67.98 | 2024-2025 | Zurzuvae |
| Validus Pharmaceuticals LLC | $55.04 | 2024-2025 | Equetro, Equetro |
| Ironshore Pharmaceuticals INC. | $41.22 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $33.99 | 2024-2025 | Austedo Xr, Austedo Xr |
| Owp Pharmaceuticals, INC. | $24.90 | 2025 | Subvenite |
| Noven Pharmaceuticals, INC. | $23.14 | 2024 | Xelstrym |
| Lilly USA, LLC | $16.53 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacklyn Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.